Alumis' LUMUS trial misses main goals in lupus, but subgroup shows benefitSep 1Clinical readoutAlumis Incenvudeucitinib
Alumis reports long-term ONWARD3 data, keeps NDA and LUMUS timelines on trackAug 13Quarterly updateAlumis Incenvudeucitinib
Sign inSign in